High Serum S100A12 Levels Predict Poor Outcome After Acute Primary Intracerebral Hemorrhage

Qiu, Shen-Zhong; Zheng, Guan-Rong; Ma, Caiyan; Chen, Bin; Jian, Huang; Ge, Heng; Hua, Hai qing

doi:10.2147/ndt.s337041

Cited by 5 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S100 calcium-binding protein A12 (S100A12) is a calcium-binding protein that plays a vital role in various diseases [ 21 ]. In ischemia-reperfusion (I/R) injury, S100A12 promotes inflammation, oxidative stress, and apoptosis by activating ERK signaling in vitro [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, therapy that targets inflammation and oxidative stress may become a potential treatment strategy for patients with AMI. S100 calcium-binding protein A12 (S100A12) is a calcium-binding protein that plays a vital role in various diseases [21]. In ischemia-reperfusion (I/R) injury, S100A12 promotes inflammation, oxidative stress, and apoptosis by activating ERK signaling in vitro [22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation and Oxidative Stress Role of S100A12 as a Potential Diagnostic and Therapeutic Biomarker in Acute Myocardial Infarction

Xie

Luo

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is one of the most serious cardiovascular diseases with high morbidity and mortality. Numerous studies have indicated that S100A12 may has an essential role in the occurrence and development of AMI, and in-depth studies are currently lacking. The purpose of this study is to investigate the effect of S100A12 on inflammation and oxidative stress and to determine its clinical applicability in AMI. Here, AMI datasets used to explore the expression pattern of S100A12 in AMI were derived from the Gene Expression Omnibus (GEO) database. The pooled standard average deviation (SMD) was calculated to further determine S100A12 expression. The overlapping differentially expressed genes (DEGs) contained in all included datasets were recognized by the GEO2R tool. Then, functional enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, were carried out to determine the molecular function of overlapping DEGs. Gene set enrichment analysis (GSEA) was conducted to determine unrevealed mechanisms of S100A12. Summary receiver operating characteristic (SROC) curve analysis and receiver operating characteristic (ROC) curve analysis were carried out to identify the diagnostic capabilities of S100A12. Moreover, we screened miRNAs targeting S100A12 using three online databases (miRWalk, TargetScan, and miRDB). In addition, by comprehensively using enzyme-linked immunosorbent assay (ELISA), real-time quantitative PCR (RT–qPCR), Western blotting (WB) methods, etc., we used the AC16 cells to validate the expression and underlying mechanism of S100A12. In our study, five datasets related to AMI, GSE24519, GSE60993, GSE66360, GSE97320, and GSE48060 were included; 412 overlapping DEGs were identified. Protein-protein interaction (PPI) network and functional analyses showed that S100A12 was a pivotal gene related to inflammation and oxidative stress. Then, S100A12 overexpression was identified based on the included datasets. The pooled standard average deviation (SMD) also showed that S100A12 was upregulated in AMI ( SMD = 1.36 , 95% CI: 0.70-2.03, p = 0.024 ). The SROC curve analysis result suggested that S100A12 had remarkable diagnostic ability in AMI ( AUC = 0.90 , 95% CI: 0.87-0.92). And nine miRNAs targeting S100A12 were also identified. Additionally, the overexpression of S100A12 was further confirmed that it maybe promote inflammation and oxidative stress in AMI through comprehensive in vitro experiments. In summary, our study suggests that overexpressed S100A12 may be a latent diagnostic biomarker and therapeutic target of AMI that induces excessive inflammation and oxidative stress. Nine miRNAs targeting S100A12 may play a crucial role in AMI, but further studies are still needed. Our work provides a positive inspiration for the in-depth study of S100A12 in AMI.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inflammation and Oxidative Stress Role of S100A12 as a Potential Diagnostic and Therapeutic Biomarker in Acute Myocardial Infarction

Xie

Luo

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The severity of stroke was assessed by the National Institute of Health stroke scale (NIHSS) score in patients with ICH at admission, and the NIHSS score was performed on ICH patients every 3 hours thereafter. An increase in the NIHSS score ≥4 was defined as early neurological deterioration [ 17 , 18 ]. All ICH patients were followed for 3 months after intracerebral hemorrhage or death.…”

Section: Methodsmentioning

confidence: 99%

“…All ICH patients were followed for 3 months after intracerebral hemorrhage or death. At 3 months after intracerebral hemorrhage, the modified rankin scale (mRS) was used to evaluate the outcome after the hemorrhage, and a mRS score >2 at 3 months after intracerebral hemorrhage was defined as poor prognosis [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

Relationship of Serum IL-12 to Inflammation, Hematoma Volume, and Prognosis in Patients With Intracerebral Hemorrhage

Zhang

Tian

Wei

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

Objective. Inflammatory cascades and hematomas after intracerebral hemorrhage (ICH) cause brain tissue and neuronal damage. Interleukin-12 (IL-12) promotes brain inflammation, and regulates coagulation mediated by red blood cells and platelets. This study was designed to investigate the relationship of serum IL-12 to inflammation, hematoma volume, and prognosis in ICH patients. Methods. We recruited patients with ICH within 12 hours of symptom onset (n = 209) and measured their serum IL-12 levels. Patients with an increased National Institute of Health stroke scale (NIHSS) score ≥4 were defined as early neurological deterioration, and modified rankin scale (mRS) score >2 at 3 months after intracerebral hemorrhage was defined as poor prognosis. Results. Levels of serum IL-12 was positively correlated with the admission of NIHSS scores (r = 0.535, P < 0.001 ), hematoma volume (r = 0.608, P < 0.001 ), serum CRP levels (r = 0.561, P < 0.001 ), and serum TNF-α levels (r = 0.533, P < 0.001 ) in 209 cases ICH patients. Levels of IL-12 in ICH patients with early neurological deterioration (median: 82.9 versus 65.8, P < 0.001 ) or with poor prognosis (median: 79.0 versus 65.3, P < 0.001 ) were all significantly higher than those in other ICH patients. In addition, serum IL-12 levels could be used to differentiate ICH patients at risk for early neurological deterioration with an AUC of 0.788 (95% CI: 0.717–0.858) or ICH patients at risk for suffering from an unfavorable outcome with an AUC of 0.787 (95% CI: 0.722–0.851). Conclusion. Elevated admission serum IL-12 levels are closely related to the inflammation, hematoma volume, and prognosis in ICH patients. Substantializing serum IL-12 levels is a prognostic biomarker for ICH.

show abstract

“…However, numerous predictors of poor outcomes after ICH have been suggested, including hematoma volume, hematoma expansion, perihematomal edema (PHE), and the presence and quantity of intraventricular hemorrhage growth [4][5][6][7]. Similarly, researchers continue to search for various blood-based biomarkers to guide management and predict outcomes after acute ICH [8][9][10][11][12]. A growing number of studies have shown that many novel biomarkers, such as C-reactive protein (CRP), S100A12, and interleukin-6, are associated with adverse outcomes in patients with ICH [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Blood-Based Biomarkers in Intracerebral Hemorrhage

Lv,

Li,

2023

JCM

View full text Add to dashboard Cite

Intracerebral hemorrhage (ICH) is one of the most lethal subtypes of stroke, associated with high morbidity and mortality. Prevention of hematoma growth and perihematomal edema expansion are promising therapeutic targets currently under investigation. Despite recent improvements in the management of ICH, the ideal treatments are still to be determined. Early stratification and triage of ICH patients enable the adjustment of the standard of care in keeping with the personalized medicine principles. In recent years, research efforts have been concentrated on the development and validation of blood-based biomarkers. The benefit of looking for blood candidate markers is obvious because of their acceptance in terms of sample collection by the general population compared to any other body fluid. Given their ease of accessibility in clinical practice, blood-based biomarkers have been widely used as potential diagnostic, predictive, and prognostic markers. This review identifies some relevant and potentially promising blood biomarkers for ICH. These blood-based markers are summarized by their roles in clinical practice. Well-designed and large-scale studies are required to validate the use of all these biomarkers in the future.

show abstract

High Serum S100A12 Levels Predict Poor Outcome After Acute Primary Intracerebral Hemorrhage

Cited by 5 publications

References 34 publications

Inflammation and Oxidative Stress Role of S100A12 as a Potential Diagnostic and Therapeutic Biomarker in Acute Myocardial Infarction

Inflammation and Oxidative Stress Role of S100A12 as a Potential Diagnostic and Therapeutic Biomarker in Acute Myocardial Infarction

Relationship of Serum IL-12 to Inflammation, Hematoma Volume, and Prognosis in Patients With Intracerebral Hemorrhage

Blood-Based Biomarkers in Intracerebral Hemorrhage

Contact Info

Product

Resources

About